Using Tumor Models to Determine Treatments
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Brigatinib
Related studies linked through entity extraction aliases.
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Status
- COMPLETED
- Phase
- N/A
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
- Status
- UNKNOWN
- Phase
- PHASE2
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Status
- COMPLETED
- Phase
- N/A
Brigatinib Before Brain Irradiation Trial (B3i Trial)
- Status
- TERMINATED
- Phase
- PHASE2
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Status
- RECRUITING
- Phase
- PHASE2
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
- Status
- UNKNOWN
- Phase
- PHASE2
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1